Current Challenges in Outcome Transparency Healthcare in Dutch Medical Specialist Care

In this update we highlight the persistent shortcomings in outcome transparency in Netherland’s healthcare system. The 2026 baseline measurement report published by Zorginstituut Nederland and Patiëntenfederatie Nederland shows that national ambitions for transparency of care outcomes in medical specialist care have not been achieved. Progress has stagnated in recent years, with the number of conditions featuring at least one publicly available outcome indicator remaining essentially unchanged at 25 since 2020.

Policy Promises vs Reality

The most impactful finding is the clear disconnect between stated policy goals and actual delivery. Despite repeated commitments in the Hoofdlijnenakkoord, Integraal Zorgakkoord, and Aanvullend Zorg- en Welzijnsakkoord, the share of outcome indicators within the total set of quality indicators has declined from 32% to 29%. Only 11.5% of the total disease burden (measured in DALYs) is currently covered by at least one transparent outcome indicator. This falls far short of the repeatedly postponed target of 50% of disease burden.

Stagnation Across Key Metrics

Between 2018 and 2025 the total number of conditions on the Transparantiekalender fell from 44 to 32, while the subset with at least one outcome indicator stayed flat at approximately 25 conditions after 2020. The absolute number of outcome indicators increased only marginally from 84 in 2020 to 86 in 2025, and their relative share actually decreased. Patient-reported outcome measures (PROMs) remain severely underdeveloped: only 15 of 32 conditions have any PROM-related indicator, and just three conditions report a PROM difference score, covering roughly 1% of total disease burden.

How Disease Burden Coverage Was Calculated

The baseline measurement systematically reviewed the official Transparantiekalender for reporting years 2014–2025. Outcome indicators are defined as measures that reflect the results of care for the patient. Disease burden is quantified in DALYs, consistent with the national target framework. Sensitivity analyses using stricter criteria reduced the covered disease burden to 9.4% and 1.2% respectively.

Consequences for Value-Based Healthcare

The persistent gap between ambition and reality has direct consequences for value-based healthcare in the Netherlands. With transparent outcome data available for only 11.5% of disease burden, stakeholders lack the robust, patient-relevant information required for informed shared decision-making or outcome-linked reimbursement models.

This situation limits the ability of payers and policy makers to implement value-based pricing. The report, available from Zorginstituut Nederland, highlights structural barriers including administrative burden and fragmented data infrastructure.

Path Forward for Outcome Transparency

Future annual repetitions of this measurement, combined with the planned implementation route and transparency assessment framework, may create gradual momentum. However, until coverage approaches the 50% target, significant information asymmetry will remain when assessing the real-world performance of medical interventions. Coordinated investment in data standardization, registry interoperability, and PROM collection is urgently needed if outcome transparency in healthcare is to become a functional tool for improving patient-centered resource allocation.